Point-Of-Care Virus Testing

Co-Diagnostics Offers an Assay Development Strategy

Co-Diagnostics has completed an assay development strategy for the Bundibugyo virus, the strain of Ebola responsible for a recent outbreak in the Democratic Republic of the Congo and Uganda that led the World Health Organization to declare a public health emergency of international concern on May 17, 2026. Co-Diagnostics has stated it is prepared to rapidly make the test available on its Co Dx PCR point of care platform should the need arise.

Additionally, the Co-Diagnostics platform's cloud-connected architecture also means that public health authorities could track cases in near real time, leading to more targeted containment measures — from localized travel advisories to hospital preparedness efforts.

Even for someone who never contracts Ebola, the same platform and assay development approach could be adapted for other pathogens.

Image Credit: Co-Diagnostics

Rapid Point-of-care PCR
Decentralized PCR devices capable of delivering lab-grade results at the bedside could shorten diagnostic timelines and shift testing away from centralized laboratories.
Cloud-connected Disease Surveillance
Near real-time case reporting via cloud-linked diagnostics may enable fine-grained public health visibility and predictive outbreak modeling.
Modular Assay Development
A platform approach that allows rapid assay adaptation for new pathogens could compress vaccine and therapeutic trial timelines by enabling faster case identification.

Who This Affects Most

Public Health and Epidemiology
Integrated point-of-care testing with centralized data streams may transform outbreak response strategies and resource allocation at regional and national levels.
Travel and Transportation
Real-time diagnostic verification at transit hubs could redefine screening protocols and risk management for international travel networks.
Hospital and Clinical Preparedness
On-site rapid molecular diagnostics combined with predictive case data may reshape emergency department triage, isolation planning, and supply chain readiness.
SCORE
4.6 out of 10
GENDER
50% Men50% Women
MARKETTop markets: North America, Africa
GENERATION
  • Gen Alpha
  • Gen Z (primary audience)
  • Millennial (primary audience)
  • Gen X (primary audience)
POPULARITY
Popularity 22%
Activity 24%
Freshness 92%